You are here

Publications

Found 46 results
Sort by: Author Title [ Type (Asc)] Year
Filters: Author is C. Sotiriou  [Clear All Filters]
Book Chapter
Haibe-Kains B, Desmedt C, Loi S, Delorenzi M, Sotiriou C, Bontempi G. Computational Intelligence in Clinical Oncology : Lessons Learned from an Analysis of a Clinical Study. In: Applications of Computational Intelligence in Biology. Vol. 122. Applications of Computational Intelligence in Biology. ; 2008. p. 237-268.
Conference Paper
Sotiriou C, Wirapati P, Loi S, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S19.
Sotiriou C, Desmedt C, Haibe-Kains B, Harris A, Larsimont D, Buyse M, Wirapati P, Delorenzi M, Bontempi G, Piccart MJ, et al. Biological mechanisms that trigger breast cancer (BC) tumor progresion are molecular subtype dependent.
Sotiriou C, Wirapati P, Loi SM, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression profiling. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S30.
Equeter C, Ouriaghli EF, Haibe-Kains B, Stamatopoulos B, André F, Lallemand F, Filippov V, Larsimont D, Sotiriou C, Willard-Gallo K, et al. CD4+ T cells infiltrating breast tumors exhibit altered expression of T cell immune response genes in comparison with their counterparts from the lymph node and blood.
Haibe-Kains B, Sotiriou C, Bontempi G. Class Discovery and Class Prediction from Human Cancer Microarray Datasets.
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Desmedt C, Tutt A, Ellis P, Buyse M, Delorenzi M, Piccart M, et al. Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC).
Sotiriou C, Haibe-Kains B, Desmedt C, Wirapati P, Durbecq V, Harris A, Larsimont D, Bontempi G, Buyse M, Delorenzi M, et al. Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures.
Sotiriou C, C.Equeter, Ouriaghli EF, Haibe-Kains B, Durbecq V, Larsimont D, Igniatiadis M, Desmedt C, Willard-Gallo K, Piccart MJ, et al. Correlation of gene expression analysis of tumor-infiltrating CD4+ cells with immune function and survival according to different breast cancer (BC) molecular subtypes. In: of Oncology JC ASCO Annual Meeting Proceedings. Vol. 20. ASCO Annual Meeting Proceedings. ; 2008. p. .
Desmedt C, Loi SM, Haibe-Kains B, Soree A, Lallemand F, Durbecq V, Larsimont D, Tutt A, Ellis P, Gillett C, et al. Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S129.
Samatopoulos B, Equeter C, Haibe-Kains B, Soree A, Sotiriou C, Bron D, Martiat P, Lagneaux L. Gene expression comparison between B cells expressing high and low level of Zap-70 mRNA reveals distinct profiles, potential therapeutic targets and new prognostic factors for Chronic Lymphocytic Leukemia.
Desmedt C, Azambuja E, Di Leo A, Larsimont D, Durbecq V, Antoine D, Lallemand F, Haibe-Kains B, Cardoso F, Nogaret JM, et al. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-monotherapy in estrogen-receptor (ER) negative breast cancer (BC) patients.
Sotiriou C, Wirapati P, Loi S, Harris A, Bergh J, Smeds J, Farmer P, Praz V, Haibe-Kains B, Lallemand F, et al. Gene Expression Profiling in Breast Cancer Challenges the Existence of Intermediate Histological Grade.
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Piette F, Buyse M, Bontempi G, Delorenzi M, Piccart M. Is genomic grading killing histological grading ?. In: Journal of European Breast Cancer. Vol. 4. Journal of European Breast Cancer. ; 2006. p. 177.
Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus N, Piccart MJ, Speed T, McArthur GA. Overcoming tamoxifen resistance in the luminal B subtype by targeting activated HER2 (ERBB2) signaling in the absence of HER2 overexpression: tailoring treatment in hormone responsive breast cancer.
Loi S, Desmedt C, Haibe-Kains B, Lallemand F, Gillett C, Tutt A, Ryder K, Ellis P, Harris A, Smeds J, et al. Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S129.
Loi S, Piccart M, Haibe-Kains B, Desmedt C, A.Harris, Bergh J, Ellis P, Miller L, Liu E, Sotiriou C, et al. Prediction of early distant relapses on tamoxifen in early- stage breast cancer (BC): a potential tool for adjuvant aromatase inhibitor (AI) tailoring.
Desmedt C, Piette F, Cardoso F, Wang Y, Loi S, Lallemand F, Klijn J, Haibe-Kains B, Viale G, Delorenzi M, et al. TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer.
Durbecq V, Toussaint J, Haibe-Kains B, Desmedt C, Rouas G, Larsimont D, Buyse M, Bontempi G, Piccart MJ, Sotiriou C, et al. Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC).
Journal Article
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nature Medecine. 2010.
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. Clin Cancer Res [Internet]. 2008:5158-5165.
Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. Bioinformatics [Internet]. 2008:2200-2208.
Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, van't Veer L, Piccart M, Bontempi G, Sotiriou C. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics [Internet]. 2008:394.
Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart MJ, Phillips WA, McArthur GA, et al. Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers. J Clin Oncol (Meeting Abstracts). 2009:533-.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt A, Gillett C, Harris A, Bergh J, Foekens J, Klijn J, et al. Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through use of genomic grade. Journal of Clinical Oncology. 2007.

Pages

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer